← Leaderboards
Michel Sadelain
Sloan-Kettering Institute For Cancer Res
$9,562,550
Attributed
$12,564,457
Total exposure
11
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,225,982 · 12
By mechanism
P01$16,290,613 · 3
R01$4,145,858 · 2
RF1$3,326,400 · 1
P30$1,832,833 · 1
U01$1,196,280 · 2
P50$413,998 · 1
Top collaborators
- Scott W Lowe6 shared
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Marcel R M Van Den Brink$40,856,878
- Richard J O'Reilly$17,498,839
- Bo Dupont$4,366,123
- Stephen David Nimer$17,329,022
- Trudy Nan Small$1,868,595
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchBaseGene TherapyPreclinical StudyCellsProgramsGeneticRetroviridaeTechnologyTransfection /Expression VectorProductionEngineeringCell TypeLaboratoriesTissuesMalignant NeoplasmsPre-ClinicalDetectionIn VivoTumorCollaborationsImmunotherapyCellular TransductionGene Transfer
Grant awards (45)
Toward development of senolytic CAR T cells$3,326,400
RF1 · FY2025 · AG
Toward development of senolytic CAR T cells$526,481
R01 · FY2024 · AG
Toward development of senolytic CAR T cells$531,078
R01 · FY2023 · AG
Toward development of senolytic CAR T cells$535,583
R01 · FY2022 · AG
Toward development of senolytic CAR T cells$539,995
R01 · FY2021 · AG
Toward development of senolytic CAR T cells$544,277
R01 · FY2020 · AG
American Society of Gene & Cell Therapy (ASGCT)19th Annual Meeting$10,000
R13 · FY2016 · TR · contact PI
American Society of Gene & Cell Therapy (ASGCT) 18th Annual Meeting$10,000
R13 · FY2015 · TR · contact PI
GENE TRANSFER and SOMATIC CELL ENGINEERING$354,551
P30 · FY2013 · CA · contact PI
GENE TRANSFER and SOMATIC CELL ENGINEERING$206,277
P30 · FY2012 · CA · contact PI
Genetic Approaches to Cancer Immunotherapy$150,000
P01 · FY2012 · CA · contact PI
GENE TRANSFER and SOMATIC CELL ENGINEERING$411,910
P30 · FY2011 · CA · contact PI
Genetic Approaches to Cancer Immunotherapy$2,081,408
P01 · FY2010 · CA · contact PI
GENE TRANSFER and SOMATIC CELL ENGINEERING$426,348
P30 · FY2010 · CA · contact PI
Genetic Approaches to Enhance the Anti-Tumor Functions of T Lymphocytes$370,739
P01 · FY2010 · CA · contact PI
Genetic Approaches to Cancer Immunotherapy$2,049,200
P01 · FY2009 · CA · contact PI
Genetic Approaches to Enhance the Anti-Tumor Functions of T Lymphocytes$365,930
P01 · FY2009 · CA · contact PI
GENE TRANSFER and SOMATIC CELL ENGINEERING$217,052
P30 · FY2009 · CA · contact PI
Genetic Approaches to Cancer Immunotherapy$1,998,048
P01 · FY2008 · CA · contact PI
Genetic Approaches to Enhance the Anti-Tumor Functions of T Lymphocytes$357,733
P01 · FY2008 · CA · contact PI
GENE TRANSFER and SOMATIC CELL ENGINEERING$216,695
P30 · FY2008 · CA · contact PI
Genetic Approaches to Cancer Immunotherapy$1,984,035
P01 · FY2007 · CA · contact PI
Genetic Approaches to Enhance the Anti-Tumor Functions of T Lymphocytes$357,114
P01 · FY2007 · CA · contact PI
Genetic Approaches to Cancer Immunotherapy$1,999,999
P01 · FY2006 · CA · contact PI
Genetic Approaches to Enhance the Anti-Tumor Functions of T Lymphocytes$177,572
P01 · FY2006 · CA · contact PI
MEMORIAL SLOAN-KETTERING CANCER GENE THERAPY PROGRAM$2,439,650
P01 · FY2004 · CA
GLOBIN GENE TRANSFER FOR THERAPY OF SICKLE CELL ANEMIA$366,750
R01 · FY2004 · HL
MEMORIAL SLOAN-KETTERING CANCER GENE THERAPY PROGRAM$1,959,185
P01 · FY2003 · CA
GLOBIN GENE TRANSFER FOR THERAPY OF SICKLE CELL ANEMIA$366,750
R01 · FY2003 · HL
GLOBIN GENE TRANSFER FOR THERAPY OF SICKLE CELL ANEMIA$366,750
R01 · FY2002 · HL
CORE--RNA VECTOR$199,380
U01 · FY2002 · HL
TREATMENT OF BETA THALASSMIA BY VIRUS TRANSFER OF BETA G$199,380
U01 · FY2002 · HL
CORE--RETROVIRAL FACILITY$0
P01 · FY2002 · CA
TUMORICIDAL FUNCTIONS OF T LYMPHOCYTES IN PSMA TUMORS$0
P01 · FY2002 · CA
GLOBIN GENE TRANSFER FOR THERAPY OF SICKLE CELL ANEMIA$368,194
R01 · FY2001 · HL
CORE--RNA VECTOR$199,380
U01 · FY2001 · HL
TREATMENT OF BETA THALASSMIA BY VIRUS TRANSFER OF BETA G$199,380
U01 · FY2001 · HL
CORE--VECTOR 2--RETROVIRUS$126,320
P50 · FY2001 · HL
CORE--RETROVIRAL FACILITY$0
P01 · FY2001 · CA
TUMORICIDAL FUNCTIONS OF T LYMPHOCYTES IN PSMA TUMORS$0
P01 · FY2001 · CA
CORE--VECTOR 2--RETROVIRUS$287,678
P50 · FY2000 · HL
CORE--RNA VECTOR$199,380
U01 · FY2000 · HL
TREATMENT OF BETA THALASSMIA BY VIRUS TRANSFER OF BETA G$199,380
U01 · FY2000 · HL
CORE--RETROVIRAL FACILITY$0
P01 · FY2000 · CA
TUMORICIDAL FUNCTIONS OF T LYMPHOCYTES IN PSMA TUMORS$0
P01 · FY2000 · CA